Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry.
Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Ueda H, Kawai K, Nozaki Y, Hiramatsu S, Miura A, Yokoi Y, Toyoshima S, Nakashima H, Haze K, Tanaka M, Take S, Saito S, Isshiki T, Mitsudo K; j-Cypher Registry Investigators. Toyofuku M, et al. Among authors: nozaki y. Circulation. 2009 Nov 10;120(19):1866-74. doi: 10.1161/CIRCULATIONAHA.109.873349. Epub 2009 Oct 26. Circulation. 2009. PMID: 19858414
Antiplatelet therapy and long-term clinical outcome after sirolimus-eluting stent implantation: 5-year outcome of the j-Cypher registry.
Kimura T, Morimoto T, Nakagawa Y, Kadota K, Nozaki Y, Tada T, Take S, Shirota K, Ito A, Nakashima H, Fujita H, Kawasaki T, Inada T, Nakao K, Miyazaki S, Doi O, Isshiki T, Nobuyoshi M, Mitsudo K. Kimura T, et al. Among authors: nozaki y. Cardiovasc Interv Ther. 2012 Sep;27(3):181-8. doi: 10.1007/s12928-012-0109-0. Epub 2012 Jun 14. Cardiovasc Interv Ther. 2012. PMID: 22695921
Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Shiode N, Nishikawa H, Nakao K, Shirota K, Kawai K, Hiasa Y, Kadota K, Nozaki Y, Isshiki T, Sone T, Mitsudo K; j-Cypher Registry Investigators. Toyofuku M, et al. Among authors: nozaki y. JACC Cardiovasc Interv. 2013 Jul;6(7):654-63. doi: 10.1016/j.jcin.2013.03.015. JACC Cardiovasc Interv. 2013. PMID: 23866178 Free article.
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Nakamura M, Iijima R, Ako J, Shinke T, Okada H, Ito Y, Ando K, Anzai H, Tanaka H, Ueda Y, Takiuchi S, Nishida Y, Ohira H, Kawaguchi K, Kadotani M, Niinuma H, Omiya K, Morita T, Zen K, Yasaka Y, Inoue K, Ishiwata S, Ochiai M, Hamasaki T, Yokoi H; NIPPON Investigators. Nakamura M, et al. JACC Cardiovasc Interv. 2017 Jun 26;10(12):1189-1198. doi: 10.1016/j.jcin.2017.04.019. JACC Cardiovasc Interv. 2017. PMID: 28641838 Free article. Clinical Trial.
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 ACS Investigators. Watanabe H, et al. JAMA Cardiol. 2022 Apr 1;7(4):407-417. doi: 10.1001/jamacardio.2021.5244. JAMA Cardiol. 2022. PMID: 35234821 Free PMC article. Clinical Trial.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Coexistence of visceral fat and multiple risk factor accumulations is strongly associated with coronary artery disease in Japanese (the VACATION-J study).
Hiuge-Shimizu A, Kishida K, Funahashi T, Okutsu M, Kametani R, Kobayashi H, Nozaki Y, Nomura A, Yokoi H, Yoshizumi T, Ohira T, Nakamura T, Matsuzawa Y, Sumitsuji S, Shimomura I. Hiuge-Shimizu A, et al. Among authors: nozaki y. J Atheroscler Thromb. 2012;19(7):657-63. doi: 10.5551/jat.13037. Epub 2012 May 4. J Atheroscler Thromb. 2012. PMID: 22472215 Free article.
665 results